Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Rating of “Moderate Buy” by Analysts

Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) have earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $42.00.

Several equities analysts recently weighed in on CSTL shares. Wall Street Zen upgraded Castle Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Roth Capital assumed coverage on shares of Castle Biosciences in a research report on Wednesday, June 24th. They set a “buy” rating and a $40.00 price target for the company. Weiss Ratings upgraded Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. KeyCorp set a $35.00 target price on Castle Biosciences in a research note on Friday, May 29th. Finally, Robert W. Baird set a $36.00 price target on shares of Castle Biosciences in a research report on Friday, July 31st.

Insider Buying and Selling at Castle Biosciences

In other Castle Biosciences news, insider Tobin W. Juvenal sold 1,730 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $28.25, for a total transaction of $48,872.50. Following the transaction, the insider owned 78,995 shares of the company’s stock, valued at $2,231,608.75. This trade represents a 2.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Kristen M. Oelschlager sold 12,384 shares of Castle Biosciences stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $34.42, for a total value of $426,257.28. Following the completion of the transaction, the chief operating officer owned 72,649 shares of the company’s stock, valued at approximately $2,500,578.58. The trade was a 14.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 160,907 shares of company stock worth $4,679,596 over the last quarter. 6.10% of the stock is owned by corporate insiders.

Institutional Trading of Castle Biosciences

Several institutional investors have recently added to or reduced their stakes in the business. Global Retirement Partners LLC acquired a new position in shares of Castle Biosciences during the second quarter valued at $26,000. Federated Hermes Inc. bought a new position in Castle Biosciences in the 4th quarter worth approximately $26,000. Kemnay Advisory Services Inc. acquired a new stake in Castle Biosciences in the 4th quarter valued at approximately $35,000. Jones Financial Companies Lllp increased its position in Castle Biosciences by 10,592.0% in the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after acquiring an additional 2,648 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Castle Biosciences by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock valued at $55,000 after acquiring an additional 297 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Castle Biosciences Price Performance

Shares of NASDAQ:CSTL opened at $34.08 on Thursday. The business’s 50 day simple moving average is $26.73 and its 200-day simple moving average is $25.41. The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of -51.64 and a beta of 0.98. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.04 and a quick ratio of 5.85. Castle Biosciences has a 12 month low of $17.72 and a 12 month high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.34. The business had revenue of $99.86 million for the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. As a group, equities analysts forecast that Castle Biosciences will post -1.29 earnings per share for the current fiscal year.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.